27 Sep 21 | CA | Apobiologix announced that Health Canada has approved Bambevi® (biosimilar bevacizumab) in...
Pearce IP BioBlast®: w/e 08 October 2021
read more
Home / News / Pearce IP Blog
ALL BLOGS BY
Naomi Pearce
Naomi is listed in IAM Patent 1000 as one of Australia's leading patent litigators. Underpinning Naomi’s legal work is a deep understanding of the pharma/biopharma industries, resulting from first hand experience and knowledge as VP of IP in-house at global pharma giants, and Partner of a top-tier international law firm.
See Naomi's full profile
Pearce IP BioBlast®: w/e 01 October 2021
27 Sep 21 | Hikma Pharmaceuticals announced that it will acquire Custopharm for an initial cash consideration of USD...
Pearce IP BioBlast®: w/e 24 September 2021
18 Sep 21 | Merck announced that the first results from Ph III trials of Keytruda® (pembrolizumab) showed a...
Pearce IP BioBlast®: w/e 17 September 2021
13 Sep 21 | Samsung Bioepis reported on a five-year follow-up study comparing ONTRUZANT® (trastuzumab biosimilar) with...
Pearce IP BioBlast®: w/e 10 September 2021
02 Sep 21 | US | Amgen and Hospira appear ready to settle the ongoing dispute relating to Neupogen® (filgrastim). The...
Federal Court Confirms Higher Bar for Sufficiency and Support in Australian Patent Law
Nalco Patent Application Claiming Inhibitors of Silica Deposits Invalid: a Question of Scale
A recent decision of Justice Burley in the Federal Court of Australia confirms that the bar for sufficiency and...
Pearce IP BioBlast®: w/e 03 September 2021
26 Aug 21 | US | Two former executives of JHL Biotech plead guilty to conspiracy to steal trade secrets and commit...
Pearce IP BioBlast®: w/e 27 August 2021
24 Aug 21 | UCB announced that it has gained EU marketing approval for Bimzelx® (bimekizumab), an IL-17A and IL-17F...
Pearce IP BioBlast®: w/e 20 August 2021
17 Aug 21 | US | The USPTO Patent Trial and Appeal Board (PTAB) will review Amgen’s US 8,273,707 Patent (related to...
Pearce IP BioBlast®: w/e 13 August 2021
05 Aug 21 | A new study reported that the safety profiles and pharmacokinetic parameters of Amgen’s ABP980 (biosimilar...
Pearce IP BioBlast®: w/e 06 August 2021
29 Jul 21 | US | The American Academy of Ophthalmology pushed back against insurance company pressure to use new...
Pearce IP BioBlast®: w/e 30 July 2021
27 Jul 21 | Abenza and BioXpress Therapeutics announced they have formed a new partnership to support biosimilar...
Pearce IP BioBlast®: w/e 23 July 2021
19 Jul 21 | Shanghai Henlius Biotech announced that the first patient has been dosed in its Ph I clinical trial of...
Pearce IP BioBlast®: w/e 16 July 2021
12 Jul 21 | Boditech Med announced it has obtained export approval for AFIAS Adalimumab, a diagnostic kit which...
Pearce IP BioBlast®: w/e 09 July 2021
05 Jul 21 | Chong Kun Dang announced it has signed a commercialisation agreement with Menagen for Nesbell® (biosimilar...
Pearce IP BioBlast®: w/e 02 July 2021
27 Jun 21 | CN | Innovent Biologics announced China’s National Medical Products Administration has approved its...